Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Altimmune, Inc. (ALT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
5.02+0.20 (+4.15%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.82
Open4.95
Bid4.75 x 900
Ask5.30 x 1400
Day's Range4.70 - 5.07
52 Week Range3.83 - 19.46
Volume569,859
Avg. Volume850,954
Market Cap199.488M
Beta (5Y Monthly)1.35
PE Ratio (TTM)N/A
EPS (TTM)-2.11
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJan 20, 2017
1y Target Est26.43
  • Zacks

    Wall Street Analysts See a 426% Upside in Altimmune, Inc. (ALT): Can the Stock Really Move This High?

    The average of price targets set by Wall Street analysts indicates a potential upside of 425.9% in Altimmune, Inc. (ALT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

  • GlobeNewswire

    Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022

    GAITHERSBURG, Md., May 20, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral presentation at the 5th Global NASH Congress on May 26-27, 2022, in London, UK. His presentation will provide an overview of pemvidutide, the Company’s novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesity and NASH. Dr. Harris

  • GlobeNewswire

    Altimmune to Present at Upcoming Investor Conferences

    GAITHERSBURG, Md., May 16, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences in May 2022: H.C. Wainwright Global Investment ConferenceTuesday, May 24, 20227:00 am Eastern TimeThe session will be webcast and can be accessed by visiting the Events section of the Altimmune website. B. Riley Securities Institutional Investor Conference

Advertisement
Advertisement